Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults

Diabetologia

Volumn 60, Issue 11, 2017, Pages 2183-2191

  Simmons, Rebecca K ^a,b,c,d,e   Griffin, Simon J ^a,c,f   Witte, Daniel R ^c,d   Borch Johnsen, Knut ^g   Lauritzen, Torsten ^c   Sandbæk, Annelli ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b STENO DIABETES CENTER   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e Aarhus Institute of Advanced Studies   (Denmark)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g HOLBÆK HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; General practice; Mortality rate; Population; Screening; Type 2 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; COMPLICATION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PROCEDURES; RISK FACTOR;

GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS;

EID: 85027850097     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4323-2     Document Type: Article

References (34)

1. Department of Health (2008) Putting prevention first. Vascular checks: risk assessment and management. Department of Health, London
2. Siu AL (2015) Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. preventive services task force recommendation statement. Ann Intern Med 163:861–868
3. Kuo HS, Chang HJ, Chou P, Teng L, Chen TH (1999) A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 28:233–240
4. Chang HJ, Kuo HS, Tung TH, Chou P, Chen TH (2000) Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan. Prev Med 31:396–402
5. Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374
6. Schuetz CA, Alperin P, Guda S et al (2013) A standardized vascular disease health check in Europe: a cost-effectiveness analysis. PLoS One 8:e66454
7. Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care 38:1449–1455
8. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748
9. Jorgensen T, Jacobsen RK, Toft U, Aadahl M, Glumer C, Pisinger C (2014) Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 348:g3617
10. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gotzsche PC (2012) General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev, Issue 10, Art. no.: CD009009. doi: 10.1002/14651858.CD009009.pub2
11. Blomstedt Y, Norberg M, Stenlund H et al (2015) Impact of a combined community and primary care prevention strategy on all-cause and cardiovascular mortality: a cohort analysis based on 1 million person-years of follow-up in Vasterbotten County, Sweden, during 1990–2006. BMJ Open 5:e009651
12. Prasad V, Lenzer J, Newman DH (2016) Why cancer screening has never been shown to “save lives” and what we can do about it. BMJ 352:h6080
13. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 24(Suppl 3):S6–S11
14. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573
15. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733
16. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
17. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553
18. Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167
19. Dansk Selskab for Almen Medicin (1998) Forebyggelse af hjertesygdom i almen praksis – med særligt henblik på dyslipidæmi. Updated 2002 and 2007. Copenhagen: Dansk Selskab for Almen Medicin [paper in Danish]
20. UNESCO (1997) International Standard Classification of Education 1997. United Nations Educational, Scientific and Cultural Organization, Paris
21. Huber PJ (1967) The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability 1: 221–233
22. Simmons RK, Rahman M, Jakes RW et al (2011) Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 54:312–319
23. Sargeant LA, Simmons RK, Barling RS et al (2010) Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med 27:995–1003
24. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328
25. Rasmussen SS, Johansen NB, Witte DR et al (2016) Incidence of register-based diabetes 10 years after a stepwise diabetes screening programme: the ADDITION-Denmark study. Diabetologia 59:989–997
26. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ (2002) What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J Med Screen 9:187–190
27. Robson J, Dostal I, Sheikh A et al (2016) The NHS health check in England: an evaluation of the first 4 years. BMJ Open 6:e008840
28. Graversen L, Christensen B, Borch-Johnsen K, Lauritzen T, Sandbaek A (2011) Lipid-lowering drugs as primary prevention in general practice: do patients reach guideline goals and continue treatment? ADDITION Denmark. Scand J Prim Health Care 29:216–221
29. Graversen L, Christensen B, Borch-Johnsen K, Lauritzen T, Sandbaek A (2010) General practitioners' adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark. Scand J Prim Health Care 28:47–54
30. Simmons RK, Carlsen AH, Griffin SJ et al (2014) Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-Denmark trial. Diabet Med 31:1577–1585
31. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J (2007) Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:490
32. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:486
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 359:1577–1589
34. Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A (2017) Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. doi:10.1007/s00125-017-4299-y